{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056202","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.259987+00:00","generated_at":"2026-06-28T10:10:13.266686+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Relay Therapeutics Q3 net loss $60.8M; cash + offering totals ~$1B, runway into 2025","bullets":["Net loss $60.8M ($0.66/share) vs $36.1M ($3.00/share) Q3 2020; R&D expenses nearly doubled to $45.0M.","Cash, equivalents, investments $616.5M at Sept 30, plus $402M net from follow-on offering, providing runway at least into 2025.","RLY-4008 interim data show selective FGFR2 inhibition; co to select RP2D and start expansion cohorts by end of 2021.","RLY-2608 preclinical data support it as first allosteric pan-mutant selective PI3Kα inhibitor; combination data at SABCS Dec 2021.","Follow-on public offering raised $402M gross proceeds, completed after quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056202","json":"https://secwatch.observer/filing/0001564590-21-056202.json","markdown":"https://secwatch.observer/filing/0001564590-21-056202.md","text":"https://secwatch.observer/filing/0001564590-21-056202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000156459021056202/0001564590-21-056202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000156459021056202/rlay-8k_20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:10:13.266686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}